Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析

◆英語タイトル:Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C13799
◆発行会社(調査会社):GlobalData
◆発行日:2019年2月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Lonza Group Ltd (LONN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lonza Group Ltd (Lonza) is a provider of contract manufacturing and development solutions to life-science industry. The company offers services including, commercial mammalian and microbial manufacturing, clinical development and manufacturing. It also offers high potential active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. Lonza provides solutions for health and well-being, microbial and hygiene control, and composites and material protection. Lonza serves biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; formulators and service companies. The company operates manufacturing and R&D facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd Key Recent Developments

Feb 13,2019: Emerald Health Pharmaceuticals and Lonza announce agreement for manufacturing of novel cannabinoid-derived drug candidate
Feb 11,2019: Lonza’s new pooled donor suspension hepatocytes enable the next level of reliability, robustness and customizability
Jan 31,2019: Lonza CEO Richard Ridlinger to Step Down This Year
Jan 30,2019: Lonza achieved another excellent full-year result in 2018 with 9% organic sales growth and strong profitability driven by healthcare businesses
Jan 30,2019: Lonza announces succession of CEO

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Lonza Group Ltd – Key Facts
Lonza Group Ltd – Key Employees
Lonza Group Ltd – Key Employee Biographies
Lonza Group Ltd – Key Operational Employees
Lonza Group Ltd – Major Products and Services
Lonza Group Ltd – History
Lonza Group Ltd – Company Statement
Lonza Group Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Lonza Group Ltd – Business Description
Business Segment: Pharma & Biotech
Overview
Performance
Business Segment: Specialty Ingredients
Overview
Performance
R&D Overview
Lonza Group Ltd – Corporate Strategy
Lonza Group Ltd – SWOT Analysis
SWOT Analysis – Overview
Lonza Group Ltd – Strengths
Lonza Group Ltd – Weaknesses
Lonza Group Ltd – Opportunities
Lonza Group Ltd – Threats
Lonza Group Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Lonza Group Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 13, 2019: Emerald Health Pharmaceuticals and Lonza announce agreement for manufacturing of novel cannabinoid-derived drug candidate
Feb 11, 2019: Lonza’s new pooled donor suspension hepatocytes enable the next level of reliability, robustness and customizability
Jan 30, 2019: Lonza achieved another excellent full-year result in 2018 with 9% organic sales growth and strong profitability driven by healthcare businesses
Jan 30, 2019: Lonza announces succession of CEO
Jan 15, 2019: Lonza announces retirement of Fridtjof Helemann
Jan 08, 2019: The world’s first fully automated plate-based robotic solution for high precision in endotoxin detection
Dec 10, 2018: Lonza to establish Strategic Biomanufacturing base in China using GE Healthcare Solution
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Lonza Group Ltd, Key Facts
Lonza Group Ltd, Key Employees
Lonza Group Ltd, Key Employee Biographies
Lonza Group Ltd, Key Operational Employees
Lonza Group Ltd, Major Products and Services
Lonza Group Ltd, History
Lonza Group Ltd, Subsidiaries
Lonza Group Ltd, Joint Venture
Lonza Group Ltd, Key Competitors
Lonza Group Ltd, Annual Ratios
Lonza Group Ltd, Annual Ratios (Cont...1)
Lonza Group Ltd, Annual Ratios (Cont...2)
Lonza Group Ltd, Interim Ratios
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Lonza Group Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Lonza Group Ltd, Performance Chart (2014 - 2018)
Lonza Group Ltd, Ratio Charts
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Merck & Co Inc (MRK):企業の財務・戦略的SWOT分析
    Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Medigen Biotechnology Corp (3176)-製薬・医療分野:企業M&A・提携分析
    Summary Medigen Biotechnology Corp (MBC) is a pharmaceutical company that carries out the research and development of biopharmaceuticals for the treatment of liver diseases and cancers. It focuses at developing new therapeutics, principally in the area of cancer and liver diseases. The company’s pro …
  • Kazia Therapeutics Ltd (KZA):製薬・医療:M&Aディール及び事業提携情報
    Summary Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (A …
  • Abbott Molecular Inc-医療機器分野:企業M&A・提携分析
    Summary Abbott Molecular Inc (Abbott Molecular), a subsidiary of Abbott Laboratories is a medical diagnostic company that provides molecular testing solutions. The company’s products include infectious disease products, oncology products, genetics products, automation products, molecular diagnostics …
  • Octapharma AG:企業の戦略・SWOT・財務情報
    Octapharma AG - Strategy, SWOT and Corporate Finance Report Summary Octapharma AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Connecticut Municipal Electric Energy Cooperative:企業の戦略的SWOT分析
    Connecticut Municipal Electric Energy Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competi …
  • Soditech Ingenierie SA (SEC):企業の財務・戦略的SWOT分析
    Soditech Ingenierie SA (SEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Duke Energy Ohio Inc:企業の戦略的SWOT分析
    Duke Energy Ohio Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • TOLMAR Inc-製薬・医療分野:企業M&A・提携分析
    Summary TOLMAR Inc (TOLMAR), a subsidiary of Tolmar Holding Inc is a developer, manufacturer and distributor of pharmaceutical products. The company provides generic dermatology products such as creams, gels, ointments and solutions. It also provides levetiracetam oral solutions including antiepilep …
  • Allianz Group:企業のM&A・事業提携・投資動向
    Allianz Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allianz Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Sourcenext Corp (4344):企業の財務・戦略的SWOT分析
    Sourcenext Corp (4344) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • MTY Food Group Inc.:戦略・SWOT・企業財務分析
    MTY Food Group Inc. - Strategy, SWOT and Corporate Finance Report Summary MTY Food Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Regis Corporation (RGS):企業の財務・戦略的SWOT分析
    Regis Corporation (RGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Agfa-Gevaert N.V. (AGFB):企業の財務・戦略的SWOT分析
    Agfa-Gevaert N.V. (AGFB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Permian Basin Royalty Trust (PBT):企業の財務・戦略的SWOT分析
    Summary Permian Basin Royalty Trust (Permian Basin Royalty) is an oil and gas company that owns overriding royalty rights in mineral properties in the US. The company provides oil and gas products. It has assets comprises of 75 percent net overriding royalty interest in the Waddell Ranch Properties …
  • Aura Light International AB:企業の戦略的SWOT分析
    Aura Light International AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Oil India Ltd (OIL):企業の財務・戦略的SWOT分析
    Oil India Ltd (OIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Brambles Limited (BXB):企業の財務・戦略的SWOT分析
    Brambles Limited (BXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Zhejiang Jolly Pharmaceutical Co Ltd (300181):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Jolly Pharmaceutical Co Ltd (Zhejiang Jolly Pharma) is a producer and marketer of pharmaceutical products. The company offers products in the form of tablets, capsules, granules, injections, dry powders, and others. Its products include Wuling powder, pseudomonas moth powder, cordyc …
  • Biocon Ltd (BIOCON):製薬・医療:M&Aディール及び事業提携情報
    Summary Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆